All In Biotech

Drug Trial Radar · NCT07842393

A Study of IBI3042 in Healthy Adult Participants

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of IBI3042 in Healthy Adult Participants

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Oct 20, 2026

Primary completion

Mar 2, 2027

Study completion Mar 2, 2027

Sponsor

Lead sponsor
Fortvita Biologics (USA)Inc.Industry
Sponsor type
Industry
First posted
Sep 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, investigator- and participant-blinded, placebo-controlled, parallel-group, dose-escalation Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of single ascending oral doses of IBI3042, in healthy adult participants. Approximately 32 healthy participants will be enrolled across 4 single ascending dose groups, with 8 participants per group randomized in a 6:2 ratio to receive a single oral dose of IBI3042 or matching placebo. A sentinel-dosing design is used for the first dose cohort. Safety and PK data are assessed to support dose escalation decisions by the Safety Review Committee.

Conditions

  • Healthy Volunteers (HV)

Interventions

  • Investigational Drug: IBI3042Drug

    Oral, corresponding dose regimen according to study cohort

  • Matching PlaceboDrug

    Oral, matching to IBI3042, corresponding dose regimen according to study cohort

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse EventsTime frame: through study completion, an average of 29 days
  2. Number of Participants With Clinically Significant Abnormal Vital SignsTime frame: through study completion, an average of 29 days
  3. Number of Participants With Clinically Significant Abnormal 12-lead electrocardiogramTime frame: through study completion, an average of 29 days
  4. Number of Participants With Abnormal General Appearance FindingsTime frame: through study completion, an average of 29 days
  5. Number of Participants With Abnormal Respiratory FindingsTime frame: through study completion, an average of 29 days
  6. Number of Participants With Abnormal Cardiovascular FindingsTime frame: through study completion, an average of 29 days
  7. Number of Participants With Abnormal Abdominal FindingsTime frame: through study completion, an average of 29 days
  8. Number of Participants With Abnormal Skin FindingsTime frame: through study completion, an average of 29 days
  9. Number of Participants With Abnormal Head and Neck FindingsTime frame: through study completion, an average of 29 days
  10. Number of Participants With Abnormal Lymph Node FindingsTime frame: through study completion, an average of 29 days
  11. Number of Participants With Abnormal Thyroid FindingsTime frame: through study completion, an average of 29 days
  12. Number of Participants With Abnormal Musculoskeletal FindingsTime frame: through study completion, an average of 29 days
  13. Number of Participants With Abnormal Neurological FindingsTime frame: through study completion, an average of 29 days
  14. Number of Participants With Abnormal Blood Routine FindingsTime frame: through study completion, an average of 29 days
  15. Number of Participants With Abnormal Blood Biochemistry FindingsTime frame: through study completion, an average of 29 days
  16. Number of Participants With Abnormal Coagulation FindingsTime frame: through study completion, an average of 29 days
  17. Number of Participants With Abnormal Urine Routine FindingsTime frame: through study completion, an average of 29 days
  18. Number of Participants With Abnormal Calcitonin FindingsTime frame: through study completion, an average of 29 days
  19. Number of Participants With Abnormal Glycated Hemoglobin FindingsTime frame: through study completion, an average of 29 days
  20. Number of Participants With Abnormal Infection-Related Immunology FindingsTime frame: through study completion, an average of 29 days
  21. Number of Participants With Abnormal Thyroid Function FindingsTime frame: through study completion, an average of 29 days
  22. Number of Participants With Abnormal Pregnancy Test FindingsTime frame: through study completion, an average of 29 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON Lenexa

    Lenexa, Kansas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.